RE:RE:RE:RE:Stock PriceDJDawg wrote: When we have days like this it always feel strange. Because it is not based on any actual information or changes in the underlying asset (the company). I've hated saying it but it feels manipulated sometimes. I just don't see a large group of investors deciding to exit NOW and at these price points when the clinical data is good and they still have a number of months of cash left from the last PP. I can see some gunshy people rushing to sell when they see this happening because in the past it is usually a prelude to an announcement about another PP. I personally feel that RDW has to know that the PP well is dry. He needs to make a suboptimal deal with someone (sell the potential GBM rights for all of Japan or Turkey or something like that) and get cash that way. A terrible deal gets you cash to start GBM is still a really good deal compared to nothing progressing. Regional licensing deals are common in biotech and should be doable
On another note:
I wonder if the big push on PR in the past week is partly to great more of a web presence for TLT so that anyone that they are working with sees that they really do exist.
Dawg, have you ever heard of a company selling rights for a pre-clinical indication before without at least having other indications already approved? It seems a stretch to me but admittedly, I don't follow the overall sector closely enough to have insights on all the various deals being closed. From my vantage point, it appears the lead indication and the impressive results to date is their only selling point for a possible licensing deal. Just why a deal hasn't been struck and why Roger's language around trying to procure non dilutive funds is so vague and passive suggests to me that up to this point they've either a) not pursued a deal urgently, b) don't have the right people/team in place to make a deal happen or c) have been rebuffed due to the apparent industry love affair with the immunotherapy endless instillation model.
With the current sp dragging along the bottom again the market continues to speak loud and clear. Very encouraging CR data and the CoB wearing his IR hat just isn't going to move the needle. The ongoing liquidity crunch will be on deck heading into end of Q1 and the sharks can easily game this one forcing yet another lower private placement. As discussed before, hopefully Roger got the memo by now but he single-handedly put a target on this company's back by doing almost quarterly under-subscribed private placements - that's just blood in the water. Only substantive news like BTD approval or a licensing deal is going to fend of ongoing shark attacks. All imo